Stomach flu vaccine shows promise in massive Kids' trial

NCT ID NCT05916326

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This large phase 3 trial tested a new norovirus vaccine in 8,000 healthy children aged 6 months to 13 years. The vaccine targets two common norovirus strains (GⅠ.1 and GⅡ.4) that cause severe vomiting and diarrhea. Researchers compared vaccinated kids to those who got a placebo to see if the shot prevents moderate to severe stomach flu.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Norovirus bivalent vaccine (GⅠ.1/GⅡ.4)
What this could lead to
If successful, this vaccine could protect children against the most common causes of severe vomiting and diarrhea from norovirus.
What could go wrong
This is a completed trial, but results are not yet published. The vaccine may not work against all norovirus strains, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

8,000 people

The number who actually took part.

Started

Jun 2023

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 13 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged from 6 months to 13 years old, and can provide legal identity certificate; * Volunteers and/or their guardians have the ability to understand the study requirements and process, agree to participate in the clinical trial and sign the informed consent, and can participate in all planned follow-up visits ( by an authorized entrusted person on the premise of written authorization by the guardian the informed consent can be signed); * Those \<12 months old: born in full-term pregnancy (gestational week 37-42 weeks) and birth weight ≥ 2.5kg. Exclusion Criteria: First dose exclusion criteria: * Axillary body temperature \> 37.0°C ; * Have a history of chronic gastrointestinal diseases; * Had gastroenteritis requiring treatment or current diarrhea, vomiting or other digestive system diseases within 7 days; * Have a history of allergy to any excipients of the experimental vaccine (L-histidine, sodium chloride, aluminum hydroxide and water for injection, etc.); * Have a history of severe allergy to any vaccine or drug, such as anaphylactic shock, allergic laryngeal edema, allergic purpura, Arthus reaction; * Have been diagnosed with congenital or acquired immunodeficiency, or received immunosuppressant treatment, such as the application of systemic glucocorticoid therapy for more than 2 consecutive weeks 2 months before vaccination, such as prednisone or similar drugs \> 5mg/day (note: use of topical and inhaled/nebulized steroids can participate); * Infectious diseases, such as: tuberculosis, viral hepatitis or parents infected with human immunodeficiency virus HIV; * Thrombocytopenia, any coagulation disorders, or intramuscular injection contraindications receiving anticoagulant therapy etc.; * The volunteer himself or his biological parents have a history of convulsions (except for febrile convulsions in children), epilepsy and mental illness; * Serious diseases or congenital malformations that may interfere with the conduct or completion of the research (including but not limited to: asthma and other respiratory diseases or during the attack of chronic bronchitis, Down syndrome, thalassemia, heart disease, encephalopathy, kidney disease, self immune diseases, genetic allergies, Guillain-Barre Syndrome, severe skin diseases, severe malnutrition, severe developmental disorders, etc.); * Asplenia, functional asplenia, and asplenia or splenectomy caused by any reason; * Have received blood or blood-related products or immune globulin within 3 months (hepatitis B immune globulin and rabies patient immune globulin are acceptable); * vaccinated inactivated/recombinant vaccines (non-live vaccines) within 7 days, and inoculate live attenuated vaccines or COVID-19 vaccines within 14 days; * Acute illness or acute exacerbation of chronic disease within 3 days; * Have taken antipyretic, analgesic or antiallergic drugs within 3 days; * Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit; * Participating in or planning to participate in another interventional research during the study process; * The investigators believe that the volunteers have other conditions that may interfere with the evaluation of the research purpose; * \<12 months old: the baby is born with abnormal labor process (dystocia, instrumental midwifery) or has a history of suffocation, nervous system damage, current pathological jaundice, perianal abscess, severe eczema; * If there have been serious adverse reactions after vaccination in the past, the investigator will determine whether the volunteer is enrolled or not according to the actual situation. If items 1, 3, 13, 14, and 15 of the exclusion criteria are met, the volunteer's enrollment will be postponed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Norovirus infections are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Jingxing County Center for Disease Control and Prevention

    Shijiazhuang, Hebei, China

  • Laishui County Center for Disease Control and Prevention

    Baoding, Hebei, China

  • Zhao County Center for Disease Control and Prevention

    Shijiazhuang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.